News
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...
President Trump shared an anecdote about a wealthy friend's experience with inflated drug prices in the U.S., prompting a ...
Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.
For us, halfway through the 2020s, it’s Mounjaro vs Ozempic, the battle of the fat jabs. In the first ever head-to-head ...
23h
The Print on MSNMounjaro vs Wegovy: Guess which obesity drug outperformed the other by a mile in head-to-head trialBoth medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
A leading obesity doctor has said a new trial of weight loss drugs Mounjaro and Wegovy may lead advertisers to reconsider their prices.
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
13h
Zacks.com on MSNRHHBY to Invest $1.25B to Boost Manufacturing Footprint in USRoche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.
14h
Pharmaceutical Technology on MSNGLP-1RAs show anti-cancer benefits beyond weight lossGlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...
Donald Trump has launched a new war, this time against pharmaceutical companies. He has signed an executive order to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results